Background-We evaluated the effect of the selective mineralocorticoid receptor antagonist eplerenone on renal function and the interaction between changes in renal function and subsequent cardiovascular outcomes in patients with heart failure and left ventricular systolic dysfunction after an acute myocardial infarction in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Methods and Results-Serial changes in estimated glomerular filtration rate (eGFR) were available in 5792 patients during a 24-month follow-up. Patients assigned to eplerenone had a decline in eGFR with an adjusted mean difference of Ϫ1.4Ϯ0.3 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 compared with placebo (PϽ0.0001), an effect that appeared within the first month (Ϫ1.3Ϯ0.4 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 ) and persisted throughout the study. Overall, 914 patients experienced a decline in eGFR Ͼ20% in the first month, 16.9% and 14.7% in the eplerenone and placebo groups, respectively (odds ratio, 1.15; 95% confidence interval, 1.02-1.30; Pϭ0.017). In multivariate analyses, determinants of this early decline in eGFR were female sex, age Ն65 years, smoking, left ventricular ejection fraction Ͻ35%, and use of eplerenone and loop diuretic. An early decline in eGFR by Ͼ20% was associated with worse cardiovascular outcomes independently of baseline eGFR and of the use of eplerenone, which retained its prognostic benefits even under these circumstances. Conclusions-In patients with heart failure after acute myocardial infarction and receiving standard medical care, an early decline in eGFR is not uncommon and is associated with poor long-term outcome. Eplerenone induced a moderately more frequent early decline in eGFR, which did not affect its clinical benefit on cardiovascular outcomes. (Circulation. 2012;125:271-279.)
I mpaired renal function is a major adverse prognostic factor in acute and chronic heart failure (HF), [1] [2] [3] [4] [5] although most pharmacological treatments that improve the prognosis of patients with HF cause a decline in renal function.
Clinical Perspective on p 279
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have prevented the progression of albuminuria and/or kidney dysfunction in various patient populations but may induce an acute deterioration in estimated glomerular filtration rate (eGFR) in HF patients. 6 -9 Mineralocorticoid receptor antagonists have also been shown to reduce proteinuria in patients with chronic kidney disease 10 -12 ; however, their long-term effect on renal function remains uncertain 10, 11 and has not been reported in HF. The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) demonstrated that the addition of the low-dose mineralocorticoid receptor antagonist eplerenone to standard medical therapy in patients with acute myocardial infarction and HF with left ventricular systolic dysfunction improved survival by 15%, with reductions in cardiovascular death, sudden death, and hospitalization for HF. 13 The aim of the present analysis was to describe the short-and long-term effects of eplerenone on kidney function and to investigate the determinants and clinical significance of changes in kidney function in the EPHESUS population.
Methods

Study Design and Patient Population
The design and main results of the EPHESUS trial have been reported previously. 13 EPHESUS enrolled 6632 patients with HF after acute myocardial infarction complicated by left ventricular systolic dysfunction (ejection fraction [EF] Յ40%). 13 HF had to be documented by at least one of the following: presence of pulmonary rales, chest radiography showing pulmonary venous congestion, or the presence of a third heart sound. Patients were entered into the study at any point from 3 to 14 days after the infarction. Patients with diabetes mellitus were not required to have evidence of HF. All patients were randomly assigned to treatment with eplerenone 25 mg daily or placebo for the first month and uptitrated to 50 mg/d or placebo, depending on serum potassium levels. Treatment with eplerenone was given in addition standard medical therapy, which could include ACEIs or ARBs, ␤-blockers, diuretics, aspirin, statins, and coronary reperfusion therapy. The study was event driven with a mean follow-up of 16 months. The present study was carried out on a subset of 5792 EPHESUS patients with available eGFR data both at baseline and at the 1-month follow-up. Moreover, 363 patients were tested for brain natriuretic peptide (Biosite) at baseline and at month 1, as previously reported. 14, 15 The study was approved by an institutional review committee, and the subjects gave informed consent.
Early Worsening of Renal Function
eGFR was computed according to the Modification of Diet in Renal Disease 4-variable formula. 16 Early worsening renal function (EWRF) was defined as a decrease in eGFR Ͼ20% at 1 month. 17 We verified that other criteria such as eGFR decline Ͼ25% 18 and serum creatinine increase Ͼ25% did not modify the present results but only reduced the number of patients with EWRF.
Plasma volume reduction was indirectly estimated with the Strauss formula 15, 19, 20 
Statistical Analysis
All analyses were performed with SAS version 9.2 (SAS Institute Inc, Cary, NC). The 2-tailed significance level was set at PϽ0.05. Continuous variables are expressed as meanϮSD or meanϮSEM), categorical variables as frequencies (percentages), and odds and hazard ratios as estimate and 95% confidence interval (95% CI). Comparisons of baseline characteristics were carried out with the Student t test and Pearson 2 test as required. The following baseline characteristics were tested in all multivariate analyses: study drug, age, sex, body mass index, smoking status, diabetes mellitus, hypertension history, left ventricular EF, mean blood pressure (MBP), blood potassium, eGFR, coronary reperfusion therapy, and treatments (loop diuretics, ACEIs or ARBs, ␤-blockers, ␣-blockers, antiarrhythmic agents, aspirin, other antiplatelet agents, statins, magnesium supplements). Validity assumptions of the models were thoroughly verified. Only significant covariables were kept in the final multivariate models through the use of an interactive stepwise backward selection method.
Change in renal function over the 24-month follow-up was assessed with mixed-effect ANCOVA with eGFR as repeated measures (baseline and 1, 3, 6, 12, 18, and 24 months), the above covariables as fixed effects, and patient as the random effect. Baseline eGFR was entered into the model to prevent the possible effect of regression toward the mean. The covariance matrix of residuals used in the models was unstructured. MBP was additionally tested as baseline, 1 month, 1-month MBP change from baseline, or time-varying covariable. Absence of interaction and collinearity, normality of residuals, and homoscedasticity were verified. The significance level of post hoc pairwise comparisons of treatments at each time point was adjusted for multiple testing with the following formula: 1Ϫ(1Ϫ␣) 1/k ϭ1Ϫ(1Ϫ0.05) 1/7 ϭ 0.0073. A sensitivity analysis was carried out on 2-year survivors. The mean annual change in eGFR occurring after EWRF was computed for each patient as the slope of the regression of the available eGFR values over time between months 1 and 24. Factors associated with EWRF were assessed with logistic regression with the above covariables and estimated plasma volume changes between baseline and month 1. Associations between EWRF and 6 adjudicated outcomes selected among the primary and secondary end points planned by the protocol (all-cause death, cardiovascular death, all-cause death or hospitalization, hospitalization for HF progression, cardiovascular death or hospitalization, and sudden cardiac death) were assessed with the Cox proportional hazards model. Assumptions of log linearity, absence of pairwise interaction and collinearity, goodness of fit (logistic regression), and proportionality of hazards (Cox models) were thoroughly verified. Age, left ventricular EF, baseline eGFR, MBP, and body mass index were necessarily expressed as binary covariables (Ն65 versus Ͻ65 years, Ͻ35% versus Ն35%, Ͻ60 versus Ն60 mL ⅐ min Ϫ1 ⅐ 1.73 m
Ϫ2
, Ͻ90 versus Ն90 mm Hg, and Ն25 versus Ͻ25 kg/m 2 , respectively) to meet the log-linearity assumption of the logistic and Cox models. Correlations between eGFR changes and estimated plasma volume or brain natriuretic peptide changes between baseline and month 1 were assessed with the Spearman correlation method.
Results
Baseline Characteristics
The number of observations available at each evaluation did not show any significant disparity between treatment groups. Of the 6632 patients of the EPHESUS study, 840 (13%) did not have creatinine data at baseline and/or at month 1, which prevented any assessment of their EWRF. These patients had generally worse clinical settings and outcomes, and 295 of the 737 patients (40%) with available baseline eGFR had values Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 compared with 33% in the 5792 analyzable patients (PϽ0.0001). Among the remaining 5792 patients, baseline characteristics were equally distributed between the 2 treatment arms (Table 1 ). In this subset, patients with eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 (Table 2 ) were generally older and sicker.
Effect of Eplerenone on eGFR
Over the first 24 months of follow-up, eGFR declined gradually in all patients. The 24-month adjusted changes from baseline were Ϫ4.6Ϯ0.9 and Ϫ2.7Ϯ0.9 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 in the eplerenone (PϽ0.0001) and placebo (Pϭ0.002) groups, respectively. The mean difference between eplerenone and placebo during the 24-month follow-up was Ϫ1.4Ϯ0.3 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 (PϽ0.0001; Figure 1A ). This difference appeared as early as the first month of treatment (baseline eGFR adjusted difference, Ϫ1.3Ϯ0.4 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 ; Pϭ0.0006) and persisted throughout the study. Subsequent to this initial decline, the mean annual changes in eGFR (computed between months 1 and 24) were similar in both groups (eplerenone versus placebo, Ϫ2.7 versus Ϫ1.8 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 ⅐ y Ϫ1 ; Pϭ0.34). These findings were supported by the results of mixed-effects models; the interaction between change over time and treatment was found to be significant for follow-up from baseline to 1 month (Pϭ0.006, ANOVA; data not shown) and from baseline to 24 months (Pϭ0.014, ANCOVA; Figure 1A ) but not from 1 to 24 months (Pϭ0.88, ANCOVA; data not shown), indicating that eGFR changes in groups differed only by the 1-month decline. This effect of eplerenone on eGFR kinetics was independent of MBP (baseline, 1 month, 1-month MBP change from baseline, or time-varying covariable) and baseline intake of loop diuretics, ACEIs/ARBs, and ␤-blockers. These results were confirmed by the sensitivity analysis in 2-year survivors, despite the loss of power caused by the radically reduced sample size ( Figure 1B ).
Determinants of Early eGFR Decline
One-month eGFR changes were not found to be correlated with the concomitant brain natriuretic peptide changes (rϭϪ0.03, Pϭ0.62, nϭ363) but were positively correlated with estimated plasma volume changes (rϭ0.09, PϽ0.0001, nϭ5382), suggesting a hemodynamic process.
Overall, 914 patients experienced an early eGFR decline Ͼ20% by 1 month: 493 (16.9%) in the eplerenone group and 421 (14.7%) in the placebo group (unadjusted odds ratio, 1.15; 95% CI, 1.02-1.30; Pϭ0.017). Among these patients, baseline characteristics were similar in the 2 groups except for aspirin intake (86% versus 90% in the eplerenone and placebo groups, respectively; Pϭ0.040). In multivariate analyses, eplerenone, baseline loop diuretics, antiarrhythmic agents, age, female sex, smoking, left ventricular EF Ͻ35%, and decrease in MBP at month 1 were associated with eGFR decline, whereas patients with baseline eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 or on statins at baseline appeared to be protected (Table 3) . Of note, estimated plasma volume change was not found to be associated with the 20% decline in eGFR (data not shown). Previous hospitalization for heart failure, n (%) 222 (8) 217 (7) 439 (8) 73 (9) Reperfusion therapy/revascularization, n (%) 1319 (46) 1334 (46) 2653 (46) 353 (42) In the setting of EWRF, hyperkalemia Ն6 mmol/L was observed in only 1 patient in the eplerenone group.
Influence of Early eGFR Decline on Cardiovascular Outcomes
Early WRF was independently associated with all 6 selected outcomes: all-cause mortality, cardiovascular death, all-cause death or hospitalization, hospitalization for HF progression, cardiovascular death or hospitalization, and sudden cardiac death (Figure 2 
Discussion
The present study provides important insights into cardiorenal interactions in HF patients after acute myocardial infarction. Eplerenone was associated with a somewhat higher rate of early deterioration in renal function. Thereafter, renal dysfunction declined at a similar rate in patients assigned to either placebo or eplerenone that was not substantially different from that reported for the normal population. The baseline severity of renal dysfunction and its early decline independently predicted an adverse outcome regardless of treatment assigned. Importantly, however, the degree of renal dysfunction and the early excess decline in eGFR did not attenuate the survival benefit in patients assigned to eplerenone.
Long-Term Eplerenone Effects on Kidney Function in HF Patients After Myocardial Infarction
This is the first report on the long-term effects of eplerenone on kidney function in patients with or at high risk of HF. The effects of mineralocorticoid receptor antagonists on kidney function have been reported in patients with chronic kidney disease and proteinuria; however, the studies were small and had a short follow-up. Long-term effects on renal outcomes, mortality, and safety are unknown. 10, 11 In EPHESUS, one third of patients had a reduced eGFR at baseline. Eplerenone did not alter the modest long-term decline in renal function that occurs in this population, which may not be substantially different from that usually occurring in the normal population. [21] [22] [23] On the contrary, an early significant, albeit modest (Ϫ1.3Ϯ0.4 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 ), detrimental effect with respect to placebo was observed, which persisted over time without any further deterioration compared with placebo. This effect on kidney function was observed independently from baseline covariates such as diabetes mellitus, baseline eGFR, concomitant medications (including ACEIs/ARBs and diuretics), EF, and MBP, as well as blood pressure variations over time. A functional hemodynamic effect resulting from blockade of the renin-angiotensin-aldosterone system was presumably involved 9 because this phenomenon occurred early with no further subsequent deterioration over time, thus ruling out a specific long-term adverse effect of eplerenone on renal function. Moreover, a weak but significant association was observed between early changes in eGFR and estimated plasma volume changes, suggesting a hemodynamic influence. Whether such a small observed decline in eGFR compared with placebo may be clinically relevant is questionable. The observed deterioration in kidney function with eplerenone in our study was consistent, although of smaller magnitude, with that observed with an ARB in the Valsartan in Heart Failure Trial (Val-HeFT; Ϫ3.6 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 in patients with chronic kidney disease patients to Ϫ4 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 in patients without chronic kidney disease compared with placebo), in which 5010 patients with characteristics similar (eg, 92% receiving ACEI) to those enrolled in the EPHESUS study were randomly assigned to receive valsartan or placebo. 6 In contrast, no significant EWRF (at 2 weeks) was observed in patients presenting with myocardial infarction and left ventricular dysfunction enrolled in the Survival and Ventricular Enlargement (SAVE) Trial, which compared captopril with placebo, without angiotensin receptor blockade or mineralocorticoid receptor antagonist. 5 Paradoxically, the subgroup of patients with eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 at inclusion in this study were not more vulnerable to further renal function deterioration. Indeed, early changes in the eGFR were smaller than in the rest of the study population. We do not have a clear explanation for this paradoxical finding. These patients did not have a smaller exposure to drug therapy that could alter hemodynamics Figure 1 . Adjusted estimated glomerular filtration rate (eGFR) changes during the 24-month (M) follow-up between the eplerenone and placebo groups. A, All patients. Study drug-by-time interaction; probability of the difference of eGFR change over time between groups. Dots and bars are least-square means and their SE estimated from adjusted mixed ANCOVA models. B, Sensitivity analysis of 2-year survivors. *Significant pairwise differences between placebo and eplerenone group levels adjusted for multiple testing. EWRF indicates early worsening renal function; OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; and MBP, mean blood pressure. EWRF is eGFR Ͼ20% at the 1-month follow-up. The OR and 95% CI are from adjusted logistic regression.
*Factors positively associated with EWRF.
and renal function such as other renin-angiotensin-aldosterone system blockers ( Table 2) . Of note, they were less likely to be revascularized, which may be associated with both contrastinduced nephropathy and cholesterol embolism. However, revascularization was not a contributing factor to the early decline in renal function in our study. In the main EPHESUS study, the subgroup analysis based on baseline serum creatinine or eGFR did not show a significant interaction. 13, 24 Taken together, our findings suggest that eplerenone is safe and beneficial in patients with HF after myocardial infarction with a serum creatinine concentration Յ2.5 mg/dL (220 mol/L) and a serum potassium concentration Յ5.0 mmol/L. 13
Influence of Baseline Kidney Dysfunction and of Early Renal Function Impairment on Cardiovascular Outcomes
Renal dysfunction is a major independent risk factor for mortality in patients with postinfarction left ventricular dysfunction and HF, as shown in the SAVE and Valsartan in Acute Myocardial Infarction (VALIANT) trials. 5, 25 Moreover, data from the Second Prospective Randomized Study of Ibopamine on Mortality and Efficacy (PRIME-II) showed that eGFR decline was a stronger predictor of mortality than EF in patients with advanced and severe chronic HF. 1 These data were subsequently confirmed by analyses of the Studies of Left Ventricular Dysfunction (SOLVD) data 26 and other trials, including the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Trial, which showed that the relationship between kidney dysfunction and poor outcome is present regardless of EF level (ie, low or preserved EF). 2 Data from the Acute Decompensated Heart Failure National Registry (ADHERE) study in patients with acute HF also showed that both blood urea nitrogen and serum creatinine (together with systolic blood pressure) were strong predictors of in-hospital mortality. 27 A recent meta- analysis also highlighted that mortality worsened incrementally across the range of renal dysfunction. 28 Consistent with previous reports in patients with acute HF syndromes, 4, 29 our results show that an increase in serum creatinine adds information value; ie, worsening renal function after 1 month was negatively associated with prognosis. A recent meta-analysis revealed that both in-hospital patients and ambulatory patients exhibited a 62% increase in mortality when experiencing an increase in serum creatinine Ͼ0.2 mg/dL (17.6 mol/L) or a corresponding decrease in eGFR Ͼ5 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 during follow-up. 3 In the present study, an early reduction in eGFR was observed in 16% of patients. Multivariate analysis identified various drugs, including eplerenone and loop diuretics, in addition to hemodynamic factors (low EF, decrease in MBP, but not plasma volume changes) as determinants of this early decline in renal function. Such findings identify factors, some of which are modifiable, that could potentially be targeted for averting this early deterioration and improve cardiovascular outcomes. Indeed, therapies specifically aimed at targeting kidney dysfunction after acute decompensated HF have so far failed to show efficacy. 30 Within this context, alternative preventive therapies are much needed. One area of investigation is a more conservative use of diuretics. Diuretic intake may be associated with adverse outcomes in CHF. Both registry data and post hoc analyses of randomized trials of other pharmacological agents have reported increased mortality and morbidity risks associated with the use of loop diuretics in patients with chronic HF. [31] [32] [33] [34] [35] The same trends were also observed in 3 short-term observational studies in patients with acute decompensated HF. 36 -38 It has been postulated that the use of loop diuretics could be an independent marker of prognosis in HF patients and/or that their long-term use per se may induce long-term pejorative effects because they may activate the renin-angiotensin-aldosterone and sympathetic nervous systems, as well as induce a decrease in GFR. 34, 39 Conversely, a short-term diuretic treatment intensification, 17, 40 aimed at relieving congestion in acute decompensated HF patients, 17 may provide long-term cardiovascular benefits. 17 Statin use in the present study was associated with a lower incidence of kidney deterioration, corroborating previous results after myocardial infarction. 41 Most important, our results show that the effects of eplerenone on kidney function did not reduce the survival benefits of eplerenone, suggesting that eplerenone should generally not be stopped if a modest decline in eGFR occurs. On the other hand, eplerenone reduced the risk of adverse outcomes in patients experiencing EWRF, although the exact threshold value required to trigger a reduction in dose or cessation of therapy cannot be determined from this trial.
Study Limitations
Our study has several limitations. First, our analysis was post hoc and included nonprespecified subgroups. However, the present data are derived from a substantial randomized controlled trial, thus allowing us to reliably assess the association among eplerenone use, kidney function, and prespecified cardiovascular outcomes. Our analysis of early changes in eGFR was focused on a 1-month time point, which could have induced a selection bias. However, a minority of patients, generally older and sicker and equally distributed between the 2 study groups (12.1% in the eplerenone group and 13.3% in the placebo group; Pϭ0.15), could not be included because of missing serum creatinine values. In addition, at this time point, the number of deaths was already smaller in the eplerenone group (107 of 3319, 3.2%) than in the placebo group (153 of 3313, 4.6%; Pϭ0.003). The external validity of our results obtained in patients with HF and altered EF after myocardial infarction (3-14 days before enrollment) and no severe (ie, Ͻ30 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 eGFR) kidney dysfunction remains to be assessed in other patient populations. Importantly, however, the changes in eGFR observed herein were of the same magnitude as that demonstrated in patients with low EF and mild symptoms in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) study. 42 In that trial, it was reported that at 1 month, the mean change in serum creatinine level from baseline was 0.15Ϯ0.35 mg/dL (13.3Ϯ30.9 mol/L) in the eplerenone group compared with 0.07Ϯ0.29 mg/dL (6.2Ϯ25.6 mol/L) in the placebo group. At the trial cutoff date, the serum creatinine level had increased from baseline by 0.09Ϯ0.37 mg/dL (8.0Ϯ32.7 mol/L) and 0.04Ϯ0.40 mg/dL (3.5Ϯ35.4 mol/L), respectively. 42 Finally, the present results were based mainly on eGFR by use of the Modification of Diet in Renal Disease formula, which accurately estimates kidney function in HF patients 43 but may be biased for eGFR Ͼ60 mL ⅐ min Ϫ1 ⅐ 1.73 m
Ϫ2
.
Conclusions
In patients with left ventricular systolic dysfunction with or at high risk of HF in the postinfarction setting, our data provide important pathophysiological insights into early changes in renal function. Adding eplerenone to standard care improves outcome in such patients even if they have moderate reductions in eGFR despite causing a slightly greater early reduction in eGFR. Eplerenone did not alter the usual long-term decline in renal function that occurs in this elderly population.
